收缩压/舒张压<140/90 mm Hg成人中的新发心血管疾病
服用降压药且血压<140/90 mm Hg者中76.6%符合他汀治疗条件但仅33.2%在使用他汀。
要点
- 多数新发心血管事件发生在血压<140/90 mm Hg的成人中。
- 服用降压药且血压达标者他汀使用率低,仅33.2%。
- 部分血压达标者符合SPRINT标准,可能受益于更低的收缩压目标。
核心结论
- 尽管较高血压水平与心血管风险增加相关,但在当代美国成人中,多数新发心血管疾病事件发生在收缩压/舒张压<140/90 mm Hg者中。
主要发现
- 平均随访7.7年,2584名参与者发生新发心血管疾病事件。
- 63.0%(95%CI 54.9-71.1)的事件发生在收缩压/舒张压<140/90 mm Hg的参与者中。
- 服用降压药者中58.4%(95%CI 47.7-69.2)、未服用者中68.1%(95%CI 60.1-76.0)的事件发生在血压<140/90 mm Hg者中。
- 服用降压药且血压<140/90 mm Hg者中,76.6%(95%CI 75.8-77.5)符合他汀治疗条件,但仅33.2%(95%CI 32.1-34.3)正在服用他汀。
- 服用降压药且血压<140/90 mm Hg者中,19.5%(95%CI 18.5-20.5)符合SPRINT入选标准,可能受益于收缩压目标120 mm Hg。
关键数值与推荐
- 血压<140/90 mm Hg者中发生事件比例:总体63.0%(95%CI 54.9-71.1)。
- 服用降压药者中血压<140/90 mm Hg的事件比例:58.4%(95%CI 47.7-69.2);未服用者:68.1%(95%CI 60.1-76.0)。
- 服用降压药且血压<140/90 mm Hg者中他汀治疗条件符合率76.6%(95%CI 75.8-77.5),实际使用率33.2%(95%CI 32.1-34.3)。
- 服用降压药且血压<140/90 mm Hg者中SPRINT入选标准符合率19.5%(95%CI 18.5-20.5)。
临床怎么用
- 对于血压<140/90 mm Hg但心血管高风险成人,应考虑额外的心血管风险降低措施。
- 服用降压药且血压达标的成人中,应评估他汀治疗指征并提高他汀使用率。
- 部分血压达标者可能符合SPRINT标准,可考虑更低的收缩压目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data from before the 2000s indicate that the majority of incident cardiovascular disease (CVD) events occur among US adults with systolic and diastolic blood pressure (SBP/DBP) ≥140/90 mm Hg. Over the past several decades, BP has declined and hypertension control has improved. METHODS: We estimated the percentage of incident CVD events that occur at SBP/DBP <140/90 mm Hg in a pooled analysis of 3 contemporary US cohorts: the REGARDS study (Reasons for Geographic and Racial Differences in Stroke), the MESA (Multi-Ethnic Study of Atherosclerosis), and the JHS (Jackson Heart Study) (n=31 856; REGARDS=21 208; MESA=6779; JHS=3869). Baseline study visits were conducted in 2003 to 2007 for REGARDS, 2000 to 2002 for MESA, and 2000 to 2004 for JHS. BP was measured by trained staff using standardized methods. Antihypertensive medication use was self-reported. The primary outcome was incident CVD, defined by the first occurrence of fatal or nonfatal stroke, nonfatal myocardial infarction, fatal coronary heart disease, or heart failure. Events were adjudicated in each study. RESULTS: Over a mean follow-up of 7.7 years, 2584 participants had incident CVD events. Overall, 63.0% (95% confidence interval [CI], 54.9-71.1) of events occurred in participants with SBP/DBP <140/90 mm Hg; 58.4% (95% CI, 47.7-69.2) and 68.1% (95% CI, 60.1-76.0) among those taking and not taking antihypertensive medication, respectively. The majority of events occurred in participants with SBP/DBP <140/90 mm Hg among those <65 years of age (66.7%; 95% CI, 60.5-73.0) and ≥65 years of age (60.3%; 95% CI, 51.0-69.5), women (61.4%; 95% CI, 49.9-72.9) and men (63.8%; 95% CI, 58.4-69.1), and for whites (68.7%; 95% CI, 66.1-71.3), blacks (59.0%; 95% CI, 49.5-68.6), Hispanics (52.7%; 95% CI, 45.1-60.4), and Chinese-Americans (58.5%; 95% CI, 45.2-71.8). Among participants taking antihypertensive medication with SBP/DBP <140/90 mm Hg, 76.6% (95% CI, 75.8-77.5) were eligible for statin treatment, but only 33.2% (95% CI, 32.1-34.3) were taking one, and 19.5% (95% CI, 18.5-20.5) met the SPRINT (Systolic Blood Pressure Intervention Trial) eligibility criteria and may benefit from a SBP target goal of 120 mm Hg. CONCLUSIONS: Although higher BP levels are associated with increased CVD risk, in the modern era, the majority of incident CVD events occur in US adults with SBP/DBP <140/90 mm Hg. While absolute risk and cost-effectiveness should be considered, additional CVD risk-reduction measures for adults with SBP/DBP <140/90 mm Hg at high risk for CVD may be warranted.
引用
- Tajeu GS, Booth JN, Colantonio LD, et al. Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg. Circulation. 2017. PMID: 28634217. doi:10.1161/CIRCULATIONAHA.117.027362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。